Products - Prostate cancer | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 40 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer (terminated appraisal) (TA1032)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
22 January 2025
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
14 August 2024
Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy (terminated appraisal) (TA994)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 August 2024
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer (TA951)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 February 2024
Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 November 2023
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer (TA903)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 June 2023
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 May 2023
Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2021
Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (TA741)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 October 2021
Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (TA721)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
18 August 2021
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
7 July 2021
Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer (TA660)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
25 November 2020
Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 May 2019
Padeliporfin for untreated localised prostate cancer (TA546)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
21 November 2018
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases (TA412)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 September 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (TA391)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
24 August 2016
Published:
25 May 2016
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 August 2016
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
27 July 2016
Published:
27 April 2016
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA377)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 July 2014
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 June 2006
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [TSID12044]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721) [ID6378]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC